+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Type 1 Diabetes Drug Market - Global Forecast 2026-2032- Product Image
Type 1 Diabetes Drug Market - Global Forecast 2026-2032- Product Image
Sale

Type 1 Diabetes Drug Market - Global Forecast 2026-2032

  • Report

  • 184 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 4985893
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Type 1 Diabetes Drug Market is projected to reach USD 22.75 Billion in 2026. It is expected to continue growing at a CAGR of 9.32%, reaching USD 39.07 Billion by 2032.

The type 1 diabetes drug market is anchored by lifelong insulin replacement, expanding use of insulin analogs, and a rising clinical focus on disease-modifying therapies that address autoimmune beta-cell destruction. Verified epidemiology underscores the commercial and public health need: CDC data show that about 2 million people in the United States live with type 1 diabetes, including more than 300,000 children and adolescents, while global research published in The Lancet estimates millions of people worldwide are affected.

Demand is shaped by earlier diagnosis, pediatric incidence growth in several regions, broader access to continuous glucose monitoring and automated insulin delivery, and payer pressure for therapies that reduce severe hypoglycemia, diabetic ketoacidosis, and long-term complications. The market is also moving beyond glycemic control toward immune intervention, exemplified by U.S. FDA approval of teplizumab to delay stage 3 type 1 diabetes in eligible patients aged 8 years and older.

Transformative Shifts in the Type 1 Diabetes Drug Landscape

The most important shift in the type 1 diabetes drug landscape is the transition from insulin-only management toward a continuum that includes prevention, delay, precision dosing, and complication reduction. Rapid-acting and long-acting insulin analogs remain essential, while biosimilar and follow-on insulin products are increasing price competition and improving formulary flexibility in major markets.

At the same time, immune-modifying drugs, beta-cell preservation strategies, stem-cell-derived islet replacement, and encapsulation technologies are reshaping R&D priorities. Regulatory agencies are increasingly open to clinically meaningful endpoints such as delaying disease onset, reducing insulin dependency, preserving C-peptide, and improving time in range, which is shifting investment toward therapies that can change the natural history of type 1 diabetes.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is becoming a cumulative force across type 1 diabetes drug discovery, clinical development, and real-world disease management. AI models are used to analyze immunologic biomarkers, genetic risk scores, electronic health records, clinical trial datasets, and glucose data to identify patients at risk of progression and support more efficient trial recruitment.

In commercial care pathways, AI-enabled insulin decision support and automated insulin delivery algorithms can improve glucose control when integrated with CGM and pump ecosystems. For drug developers, AI strengthens pharmacovigilance, adherence analytics, and comparative effectiveness research, helping demonstrate outcomes that payers increasingly require for reimbursement and long-term access.

Key Regional Insights Across Major Markets

North America remains the most advanced region for type 1 diabetes drugs, led by the United States, where high diagnosis rates, specialty endocrinology networks, continuous glucose monitoring adoption, and reimbursement for advanced diabetes technologies support uptake of premium insulin analogs and immune-therapy innovation. Canada shows strong clinical guideline alignment and public health support, although provincial reimbursement variation influences access to insulin formulations, diabetes devices, and adjunct care services.

Europe benefits from structured diabetes registries, national health systems, pediatric diabetes programs, and broad use of biosimilar insulin in cost-containment strategies. Asia-Pacific is expanding its clinical relevance as China, India, Japan, Australia, and South Korea improve screening, pediatric endocrinology capacity, reimbursement pathways, and digital diabetes management. Latin America demonstrates rising need as Brazil and Mexico expand public-sector diabetes care, though affordability and procurement consistency remain important constraints. The Middle East, particularly high-income Gulf health systems, is investing in specialty diabetes centers, digital health, and prevention programs, while Africa faces the greatest access barriers due to insulin affordability, cold-chain requirements, trained specialist shortages, and inconsistent supply across many countries.

Key Group Insights for Strategic Market Expansion

The European Union is a critical policy and reimbursement bloc for type 1 diabetes drugs because centralized regulatory pathways, evolving health technology assessment reforms, pharmacovigilance standards, and biosimilar adoption influence pricing and access across member states. The G7 concentrates advanced R&D capacity, premium treatment adoption, pediatric diabetes expertise, and payer scrutiny, making it central to evidence generation for insulin analogs, immunotherapies, beta-cell preservation, and beta-cell replacement programs.

BRICS countries represent high-volume long-term treatment expansion potential, particularly through China, India, and Brazil, where expanding healthcare coverage, domestic biologics capacity, and improving diagnosis can increase treated populations, although affordability remains a defining access issue. ASEAN markets are improving diabetes infrastructure and digital health adoption but remain price sensitive, requiring scalable insulin access models and clinician education. GCC countries are investing in specialty care, chronic disease management, and connected diabetes technologies, supporting higher adoption of advanced therapies when evidence is compelling. NATO overlap with North America and Europe reinforces high standards for supply chain resilience, regulatory quality, biologics manufacturing security, and continuity of essential insulin supply.

Key Country Insights in the Type 1 Diabetes Drug Market

The United States is the leading commercial market due to high treatment intensity, innovation adoption, strong clinical trial activity, and regulatory precedent for disease-delaying therapy. Canada, the United Kingdom, Germany, France, Italy, and Spain benefit from established endocrinology services, pediatric diabetes networks, and guideline-driven care, though reimbursement decisions are closely tied to cost-effectiveness evidence, real-world outcomes, and budget impact. Russia and Mexico present sustained demand for insulin access and affordability, with public procurement, domestic supply priorities, and distribution reliability playing significant roles.

China and India offer major long-term opportunity as diagnosis improves, healthcare investment grows, and specialist networks expand, but affordability, awareness, rural access, and availability of advanced diabetes technologies remain barriers. Japan, Australia, and South Korea show strong adoption of advanced diabetes technologies, favorable clinical infrastructure, and high standards for post-market safety monitoring. Brazil is the most important Latin American country in this set, driven by public-sector insulin access, private healthcare growth, diabetes advocacy, and increasing attention to pediatric and adolescent type 1 diabetes care.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize therapies that generate measurable clinical value beyond HbA1c, including improved time in range, lower severe hypoglycemia, reduced diabetic ketoacidosis, preserved beta-cell function, delayed progression to symptomatic disease, and better quality of life. Evidence packages should integrate randomized controlled trials with real-world data from CGM, pump, claims, electronic health record, and registry sources.

Organizations should also strengthen access strategies through tiered pricing, biosimilar partnerships, patient support programs, clinician education, and cold-chain reliability in emerging markets. For innovation portfolios, the highest-value opportunities include immune modulation, beta-cell replacement, precision insulin delivery, and AI-enabled adherence and risk stratification tools that align drug benefits with payer-relevant outcomes and practical care delivery.

Research Methodology

This executive summary is based on secondary research using verified sources such as public health agencies, regulatory databases, clinical trial registries, peer-reviewed journals, diabetes association guidance, and publicly available healthcare policy documents. The analysis prioritizes evidence from organizations including the CDC, WHO, U.S. FDA, EMA, International Diabetes Federation, and leading clinical publications.

Market interpretation applies cross-validation across epidemiology, treatment guidelines, reimbursement trends, product approvals, pipeline activity, clinical endpoints, digital diabetes adoption, and regional access conditions. Insights are structured to support strategic planning for type 1 diabetes drug developers, insulin manufacturers, biosimilar entrants, medtech partners, payers, and healthcare investors without relying on market sizing, market share, or forecasting assumptions.

Conclusion

The type 1 diabetes drug market is entering a new phase in which insulin remains foundational while disease modification, digital integration, and precision care create differentiated strategic pathways. The approval of immune therapy to delay disease onset has validated a broader preventive and interventional model for type 1 diabetes treatment.

Future leadership will depend on demonstrating durable clinical outcomes, expanding equitable access, ensuring reliable insulin supply, and combining drug innovation with data-driven care delivery. Organizations that align biologic innovation, AI-enabled evidence generation, and region-specific reimbursement strategies will be best positioned in this evolving market.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Type 1 Diabetes Drug Market, by Insulin Type
7.1. Introduction
7.2. Intermediate-Acting
7.3. Long-Acting
7.4. Rapid-Acting
7.5. Short-Acting
8. Type 1 Diabetes Drug Market, by Delivery Mode
8.1. Introduction
8.2. Pen
8.3. Pump
8.4. Syringe
9. Type 1 Diabetes Drug Market, by Route Of Administration
9.1. Introduction
9.2. Subcutaneous
9.3. Intravenous
10. Type 1 Diabetes Drug Market, by Treatment Line
10.1. Introduction
10.2. First-Line
10.3. Second-Line
10.4. Third-Line And Beyond
11. Type 1 Diabetes Drug Market, by Distribution Channel
11.1. Introduction
11.2. Offline
11.3. Online
12. Type 1 Diabetes Drug Market, by End User
12.1. Introduction
12.2. Clinics
12.3. Home Care
12.4. Hospitals
13. Type 1 Diabetes Drug Market, by Patient Age Group
13.1. Introduction
13.2. Adult
13.3. Geriatric
13.4. Pediatric
14. Type 1 Diabetes Drug Market, by Region
14.1. Asia-Pacific
14.2. North America
14.3. Latin America
14.4. Europe
14.5. Middle East
14.6. Africa
15. Type 1 Diabetes Drug Market, by Group
15.1. ASEAN
15.2. GCC
15.3. European Union
15.4. BRICS
15.5. G7
15.6. NATO
16. Type 1 Diabetes Drug Market, by Country
16.1. United States
16.2. Canada
16.3. Mexico
16.4. Brazil
16.5. United Kingdom
16.6. Germany
16.7. France
16.8. Russia
16.9. Italy
16.10. Spain
16.11. China
16.12. India
16.13. Japan
16.14. Australia
16.15. South Korea
17. Competitive Landscape
17.1. Market Share Analysis, 2025
17.2. FPNV Positioning Matrix, 2025
17.3. Market Concentration Analysis, 2025
17.3.1. Concentration Ratio (CR)
17.3.2. Herfindahl Hirschman Index (HHI)
17.4. Recent Developments & Impact Analysis, 2025
17.5. Product Portfolio Analysis, 2025
17.6. Benchmarking Analysis, 2025
18. Company Profiles
18.1. Adocia
18.2. Arecor Therapeutics PLC
18.3. AstraZeneca PLC
18.4. Biocon Limited
18.5. Bristol-Myers Squibb Company
18.6. Civica, Inc.
18.7. Diasome Pharmaceuticals Inc.
18.8. Eli Lilly and Company
18.9. Gan & Lee Pharmaceuticals Co., Ltd.
18.10. GlaxoSmithKline PLC
18.11. Johnson & Johnson Services Inc.
18.12. Lexicon Pharmaceuticals Inc.
18.13. Lupin Limited
18.14. MannKind Corporation
18.15. Merck & Co. Inc.
18.16. Mylan N.V.
18.17. Novartis AG
18.18. Novo Nordisk A/S
18.19. Pfizer Inc.
18.20. Provention Bio Inc.
18.21. Sandoz Group AG
18.22. Sanofi S.A.
18.23. Sun Pharmaceutical Industries Ltd.
18.24. Teva Pharmaceutical Industries Ltd.
18.25. Viatris Inc.
18.26. Zealand Pharma A/S
List of Figures
FIGURE 1. GLOBAL TYPE 1 DIABETES DRUG MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL TYPE 1 DIABETES DRUG MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL TYPE 1 DIABETES DRUG MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL TYPE 1 DIABETES DRUG MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2025 VS 2032 (%)
FIGURE 7. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2025 VS 2032 (%)
FIGURE 9. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
FIGURE 11. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY TREATMENT LINE, 2025 VS 2032 (%)
FIGURE 13. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY TREATMENT LINE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 15. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 17. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2032 (%)
FIGURE 19. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 21. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 23. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 25. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 26. GLOBAL TYPE 1 DIABETES DRUG MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 27. GLOBAL TYPE 1 DIABETES DRUG MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL TYPE 1 DIABETES DRUG MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL INTERMEDIATE-ACTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL INTERMEDIATE-ACTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL INTERMEDIATE-ACTING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL LONG-ACTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL LONG-ACTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL LONG-ACTING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL RAPID-ACTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL RAPID-ACTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL RAPID-ACTING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL SHORT-ACTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL SHORT-ACTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL SHORT-ACTING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL PEN MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL PEN MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL PEN MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL PUMP MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL PUMP MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL PUMP MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL SYRINGE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL SYRINGE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL SYRINGE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY TREATMENT LINE, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL FIRST-LINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL FIRST-LINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL FIRST-LINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL SECOND-LINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL SECOND-LINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL SECOND-LINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL THIRD-LINE AND BEYOND MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL THIRD-LINE AND BEYOND MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL THIRD-LINE AND BEYOND MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL OFFLINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL OFFLINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL OFFLINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL ONLINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL ONLINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL ONLINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL HOME CARE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL HOME CARE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL HOME CARE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL ADULT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL ADULT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL ADULT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL GERIATRIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL GERIATRIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL GERIATRIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL PEDIATRIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL PEDIATRIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL PEDIATRIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 71. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 72. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2017-2032 (USD MILLION)
TABLE 73. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2017-2032 (USD MILLION)
TABLE 74. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 75. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY TREATMENT LINE, 2017-2032 (USD MILLION)
TABLE 76. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 77. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 78. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 79. NORTH AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 80. NORTH AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2017-2032 (USD MILLION)
TABLE 81. NORTH AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2017-2032 (USD MILLION)
TABLE 82. NORTH AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 83. NORTH AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY TREATMENT LINE, 2017-2032 (USD MILLION)
TABLE 84. NORTH AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 85. NORTH AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 86. NORTH AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 87. LATIN AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 88. LATIN AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2017-2032 (USD MILLION)
TABLE 89. LATIN AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2017-2032 (USD MILLION)
TABLE 90. LATIN AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 91. LATIN AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY TREATMENT LINE, 2017-2032 (USD MILLION)
TABLE 92. LATIN AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 93. LATIN AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 94. LATIN AMERICA TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 95. EUROPE TYPE 1 DIABETES DRUG MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 96. EUROPE TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2017-2032 (USD MILLION)
TABLE 97. EUROPE TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2017-2032 (USD MILLION)
TABLE 98. EUROPE TYPE 1 DIABETES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 99. EUROPE TYPE 1 DIABETES DRUG MARKET SIZE, BY TREATMENT LINE, 2017-2032 (USD MILLION)
TABLE 100. EUROPE TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 101. EUROPE TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 102. EUROPE TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 103. MIDDLE EAST TYPE 1 DIABETES DRUG MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 104. MIDDLE EAST TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2017-2032 (USD MILLION)
TABLE 105. MIDDLE EAST TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2017-2032 (USD MILLION)
TABLE 106. MIDDLE EAST TYPE 1 DIABETES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 107. MIDDLE EAST TYPE 1 DIABETES DRUG MARKET SIZE, BY TREATMENT LINE, 2017-2032 (USD MILLION)
TABLE 108. MIDDLE EAST TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 109. MIDDLE EAST TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 110. MIDDLE EAST TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 111. AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 112. AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2017-2032 (USD MILLION)
TABLE 113. AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2017-2032 (USD MILLION)
TABLE 114. AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 115. AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY TREATMENT LINE, 2017-2032 (USD MILLION)
TABLE 116. AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 117. AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 118. AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 119. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 120. ASEAN TYPE 1 DIABETES DRUG MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 121. ASEAN TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2017-2032 (USD MILLION)
TABLE 122. ASEAN TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2017-2032 (USD MILLION)
TABLE 123. ASEAN TYPE 1 DIABETES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 124. ASEAN TYPE 1 DIABETES DRUG MARKET SIZE, BY TREATMENT LINE, 2017-2032 (USD MILLION)
TABLE 125. ASEAN TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 126. ASEAN TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 127. ASEAN TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 128. GCC TYPE 1 DIABETES DRUG MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 129. GCC TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2017-2032 (USD MILLION)
TABLE 130. GCC TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2017-2032 (USD MILLION)
TABLE 131. GCC TYPE 1 DIABETES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 132. GCC TYPE 1 DIABETES DRUG MARKET SIZE, BY TREATMENT LINE, 2017-2032 (USD MILLION)
TABLE 133. GCC TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 134. GCC TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 135. GCC TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 136. EUROPEAN UNION TYPE 1 DIABETES DRUG MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 137. EUROPEAN UNION TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2017-2032 (USD MILLION)
TABLE 138. EUROPEAN UNION TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2017-2032 (USD MILLION)
TABLE 139. EUROPEAN UNION TYPE 1 DIABETES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 140. EUROPEAN UNION TYPE 1 DIABETES DRUG MARKET SIZE, BY TREATMENT LINE, 2017-2032 (USD MILLION)
TABLE 141. EUROPEAN UNION TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 142. EUROPEAN UNION TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 143. EUROPEAN UNION TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 144. BRICS TYPE 1 DIABETES DRUG MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 145. BRICS TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2017-2032 (USD MILLION)
TABLE 146. BRICS TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2017-2032 (USD MILLION)
TABLE 147. BRICS TYPE 1 DIABETES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 148. BRICS TYPE 1 DIABETES DRUG MARKET SIZE, BY TREATMENT LINE, 2017-2032 (USD MILLION)
TABLE 149. BRICS TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 150. BRICS TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 151. BRICS TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 152. G7 TYPE 1 DIABETES DRUG MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 153. G7 TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2017-2032 (USD MILLION)
TABLE 154. G7 TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2017-2032 (USD MILLION)
TABLE 155. G7 TYPE 1 DIABETES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 156. G7 TYPE 1 DIABETES DRUG MARKET SIZE, BY TREATMENT LINE, 2017-2032 (USD MILLION)
TABLE 157. G7 TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 158. G7 TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 159. G7 TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 160. NATO TYPE 1 DIABETES DRUG MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 161. NATO TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2017-2032 (USD MILLION)
TABLE 162. NATO TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2017-2032 (USD MILLION)
TABLE 163. NATO TYPE 1 DIABETES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 164. NATO TYPE 1 DIABETES DRUG MARKET SIZE, BY TREATMENT LINE, 2017-2032 (USD MILLION)
TABLE 165. NATO TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 166. NATO TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 167. NATO TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 168. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 169. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 170. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2017-2032 (USD MILLION)
TABLE 171. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2017-2032 (USD MILLION)
TABLE 172. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 173. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY TREATMENT LINE, 2017-2032 (USD MILLION)
TABLE 174. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 175. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 176. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 177. CANADA TYPE 1 DIABETES DRUG MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 178. CANADA TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2017-2032 (USD MILLION)
TABLE 179. CANADA TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2017-2032 (USD MILLION)
TABLE 180. CANADA TYPE 1 DIABETES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 181. CANADA TYPE 1 DIABETES DRUG MARKET SIZE, BY TREATMENT LINE, 2017-2032 (USD MILLION)
TABLE 182. CANADA TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 183. CANADA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 184. CANADA TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 185. MEXICO TYPE 1 DIABETES DRUG MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 186. MEXICO TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2017-2032 (USD MILLION)
TABLE 187. MEXICO TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2017-2032 (USD MILLION)
TABLE 188. MEXICO TYPE 1 DIABETES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 189. MEXICO TYPE 1 DIABETES DRUG MARKET SIZE, BY TREATMENT LINE, 2017-2032 (USD MILLION)
TABLE 190. MEXICO TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 191. MEXICO TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 192. MEXICO TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 193. BRAZIL TYPE 1 DIABETES DRUG MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 194. BRAZIL TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2017-2032 (USD MILLION)
TABLE 195. BRAZIL TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2017-2032 (USD MILLION)
TABLE 196. BRAZIL TYPE 1 DIABETES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 197. BRAZIL TYPE 1 DIABETES DRUG MARKET SIZE, BY TREATMENT LINE, 2017-2032 (USD MILLION)
TABLE 198. BRAZIL TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 199. BRAZIL TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 200. BRAZIL TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 201. UNITED KINGDOM TYPE 1 DIABETES DRUG MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 202. UNITED KINGDOM TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2017-2032 (USD MILLION)
TABLE 203. UNITED KINGDOM TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2017-2032 (USD MILLION)
TABLE 204. UNITED KINGDOM TYPE 1 DIABETES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 205. UNITED KINGDOM TYPE 1 DIABETES DRUG MARKET SIZE, BY TREATMENT LINE, 2017-2032 (USD MILLION)
TABLE 206. UNITED KINGDOM TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 207. UNITED KINGDOM TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 208. UNITED KINGDOM TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 209. GERMANY TYPE 1 DIABETES DRUG MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 210. GERMANY TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2017-2032 (USD MILLION)
TABLE 211. GERMANY TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2017-2032 (USD MILLION)
TABLE 212. GERMANY TYPE 1 DIABETES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 213. GERMANY TYPE 1 DIABETES DRUG MARKET SIZE, BY TREATMENT LINE, 2017-2032 (USD MILLION)
TABLE 214. GERMANY TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 215. GERMANY TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 216. GERMANY TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 217. FRANCE TYPE 1 DIABETES DRUG MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 218. FRANCE TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2017-2032 (USD MILLION)
TABLE 219. FRANCE TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2017-2032 (USD MILLION)
TABLE 220. FRANCE TYPE 1 DIABETES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 221. FRANCE TYPE 1 DIABETES DRUG MARKET SIZE, BY TREATMENT LINE, 2017-2032 (USD MILLION)
TABLE 222. FRANCE TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 223. FRANCE TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 224. FRANCE TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 225. RUSSIA TYPE 1 DIABETES DRUG MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 226. RUSSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2017-2032 (USD MILLION)
TABLE 227. RUSSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2017-2032 (USD MILLION)
TABLE 228. RUSSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 229. RUSSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY TREATMENT LINE, 2017-2032 (USD MILLION)
TABLE 230. RUSSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 231. RUSSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 232. RUSSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 233. ITALY TYPE 1 DIABETES DRUG MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 234. ITALY TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2017-2032 (USD MILLION)
TABLE 235. ITALY TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2017-2032 (USD MILLION)
TABLE 236. ITALY TYPE 1 DIABETES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 237. ITALY TYPE 1 DIABETES DRUG MARKET SIZE, BY TREATMENT LINE, 2017-2032 (USD MILLION)
TABLE 238. ITALY TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 239. ITALY TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 240. ITALY TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 241. SPAIN TYPE 1 DIABETES DRUG MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 242. SPAIN TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2017-2032 (USD MILLION)
TABLE 243. SPAIN TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2017-2032 (USD MILLION)
TABLE 244. SPAIN TYPE 1 DIABETES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 245. SPAIN TYPE 1 DIABETES DRUG MARKET SIZE, BY TREATMENT LINE, 2017-2032 (USD MILLION)
TABLE 246. SPAIN TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 247. SPAIN TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 248. SPAIN TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 249. CHINA TYPE 1 DIABETES DRUG MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 250. CHINA TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2017-2032 (USD MILLION)
TABLE 251. CHINA TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2017-2032 (USD MILLION)
TABLE 252. CHINA TYPE 1 DIABETES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 253. CHINA TYPE 1 DIABETES DRUG MARKET SIZE, BY TREATMENT LINE, 2017-2032 (USD MILLION)
TABLE 254. CHINA TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 255. CHINA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 256. CHINA TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 257. INDIA TYPE 1 DIABETES DRUG MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 258. INDIA TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2017-2032 (USD MILLION)
TABLE 259. INDIA TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2017-2032 (USD MILLION)
TABLE 260. INDIA TYPE 1 DIABETES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 261. INDIA TYPE 1 DIABETES DRUG MARKET SIZE, BY TREATMENT LINE, 2017-2032 (USD MILLION)
TABLE 262. INDIA TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 263. INDIA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 264. INDIA TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 265. JAPAN TYPE 1 DIABETES DRUG MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 266. JAPAN TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2017-2032 (USD MILLION)
TABLE 267. JAPAN TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2017-2032 (USD MILLION)
TABLE 268. JAPAN TYPE 1 DIABETES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 269. JAPAN TYPE 1 DIABETES DRUG MARKET SIZE, BY TREATMENT LINE, 2017-2032 (USD MILLION)
TABLE 270. JAPAN TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 271. JAPAN TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 272. JAPAN TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 273. AUSTRALIA TYPE 1 DIABETES DRUG MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 274. AUSTRALIA TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2017-2032 (USD MILLION)
TABLE 275. AUSTRALIA TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2017-2032 (USD MILLION)
TABLE 276. AUSTRALIA TYPE 1 DIABETES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 277. AUSTRALIA TYPE 1 DIABETES DRUG MARKET SIZE, BY TREATMENT LINE, 2017-2032 (USD MILLION)
TABLE 278. AUSTRALIA TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 279. AUSTRALIA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 280. AUSTRALIA TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 281. SOUTH KOREA TYPE 1 DIABETES DRUG MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 282. SOUTH KOREA TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN TYPE, 2017-2032 (USD MILLION)
TABLE 283. SOUTH KOREA TYPE 1 DIABETES DRUG MARKET SIZE, BY DELIVERY MODE, 2017-2032 (USD MILLION)
TABLE 284. SOUTH KOREA TYPE 1 DIABETES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 285. SOUTH KOREA TYPE 1 DIABETES DRUG MARKET SIZE, BY TREATMENT LINE, 2017-2032 (USD MILLION)
TABLE 286. SOUTH KOREA TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 287. SOUTH KOREA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 288. SOUTH KOREA TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 289. GLOBAL TYPE 1 DIABETES DRUG MARKET SHARE, BY KEY PLAYER, 2025
TABLE 290. GLOBAL TYPE 1 DIABETES DRUG MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

Companies Mentioned

  • Adocia
  • Arecor Therapeutics PLC
  • AstraZeneca PLC
  • Biocon Limited
  • Bristol-Myers Squibb Company
  • Civica, Inc.
  • Diasome Pharmaceuticals Inc.
  • Eli Lilly and Company
  • Gan & Lee Pharmaceuticals Co., Ltd.
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services Inc.
  • Lexicon Pharmaceuticals Inc.
  • Lupin Limited
  • MannKind Corporation
  • Merck & Co. Inc.
  • Mylan N.V.
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Provention Bio Inc.
  • Sandoz Group AG
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Zealand Pharma A/S

Table Information

Report AttributeDetails
No. of Pages184
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 22.75 Billion
Forecasted Market Value ( USD ) by 2032 $ 39.07 Billion
Compound Annual Growth Rate9.3%
Regions CoveredGlobal
No. of Companies Mentioned26

Related Topics

Related Reports

Diabetes Drugs Market - Global Forecast 2026-2032 - Product Image

Diabetes Drugs Market - Global Forecast 2026-2032

  • Report
  • 182 Pages
  • Global
From
Human Insulin Drugs Market - Global Forecast 2026-2032 - Product Image

Human Insulin Drugs Market - Global Forecast 2026-2032

  • Report
  • 183 Pages
  • Global
From
Human Insulin Market Size, Share, Trends and Forecast by Product Type, Distribution Channel, Disease Type, and Region, 2026-2034 - Product Image

Human Insulin Market Size, Share, Trends and Forecast by Product Type, Distribution Channel, Disease Type, and Region, 2026-2034

  • Report
  • 149 Pages
  • Global
From
United States Diabetes Market Size, Share, Trends and Forecast by Segment, 2026-2034 - Product Image

United States Diabetes Market Size, Share, Trends and Forecast by Segment, 2026-2034

  • Report
  • 150 Pages
  • United States
From
Diabetes Drugs - Global Strategic Business Report - Product Image

Diabetes Drugs - Global Strategic Business Report

  • Report
  • 478 Pages
  • Global
From

About the Type 1 Diabetes Drug Market

The Type 1 Diabetes Drug market is a subset of the Immune Disorders Drugs market. It is composed of drugs used to treat Type 1 Diabetes, an autoimmune disorder in which the body's immune system attacks the cells that produce insulin. These drugs are used to help regulate blood sugar levels and reduce the risk of complications associated with the disease. Commonly used Type 1 Diabetes Drugs include insulin, sulfonylureas, meglitinides, and GLP-1 agonists. These drugs are typically administered orally or through injection. The Type 1 Diabetes Drug market is highly competitive, with many companies offering a variety of products. Some of the major players in the market include Novo Nordisk, Sanofi, Eli Lilly, Merck, and Boehringer Ingelheim. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.